Positioning Therapy for Crohn’s Disease
- 30 March 2014
- journal article
- review article
- Published by Springer Nature in Current Gastroenterology Reports
- Vol. 16 (6)
Abstract
The therapy of Crohn’s disease is constantly evolving. It is widely recognized that clinical assessment does not stage disease activity accurately and that endoscopic healing is associated with improved long-term outcomes. Disease management is therefore transitioning to a new paradigm that includes direct assessment of disease severity (endoscopically in most patients), followed by assessment of mucosal healing. New approaches have helped optimize the use of the thiopurines, methotrexate and anti-TNF agents. Novel agents with different mechanisms of action are expanding our therapeutic armamentarium. The major challenge of the future will be to identify patient subgroups best suited to particular therapeutic approaches. In the meantime, studies of comparative effectiveness will be crucial in positioning therapies relative to each other.Keywords
This publication has 78 references indexed in Scilit:
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's DiseaseClinical Gastroenterology and Hepatology, 2014
- Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2013
- Lymphoma: The Bête Noire of the Long-term Use of Thiopurines in Adult and Elderly Patients With Inflammatory Bowel DiseaseGastroenterology, 2013
- Mucosal Improvement in Patients With Moderate to Severe Postoperative Endoscopic Recurrence of Crohn’s Disease and Azathioprine Metabolite LevelsInflammatory Bowel Diseases, 2013
- Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: A prospective, two-year, single center, pilot studyJournal of Crohn's and Colitis, 2012
- The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically usefulGut, 2010
- Infliximab use in Crohn??s disease: impact on health care resources in the UKEuropean Journal of Gastroenterology & Hepatology, 2005
- Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurineGut, 2005
- Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trialGastroenterology, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002